Ultragenyx Pharmaceutical (MEX:RARE) Tariff Resilience Score: 6/10 (As of Jul. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:RARE Ultragenyx Pharmaceutical Inc MEX:RARE
70 GF Score
Price MXN1,150.56
GF Value MXN1,699.44
! 5 Warning Signs
View Full Analysis

What is Ultragenyx Pharmaceutical Tariff Resilience Score?

Ultragenyx Pharmaceutical MEX:RARE 70 Tariff Resilience Score is 6 as of Jul. 15, 2026. GuruFocus rates MEX:RARE with a GF Score™ of 70/100 and a GF Value™ of MXN1,699.44. The stock has 5 warning signs investors should review. Among 1,370 Biotechnology companies, Ultragenyx Pharmaceutical ranks better than 75.99% on this metric.

Ultragenyx Pharmaceutical has the Tariff Resilience Score of 6, which implies that the company might have Average Resilient.

Ultragenyx Pharmaceutical has Ultragenyx has a global supply chain but primarily focuses on the US market. While some raw materials are imported, the impact of tariffs is mitigated by the company's pricing power and the essential nature of its products, which are less sensitive to price changes.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Ultragenyx Pharmaceutical might have Average Resilient.

Ultragenyx Pharmaceutical  (MEX:RARE) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Ultragenyx Pharmaceutical Tariff Resilience Score Related Terms

MEX:RARE vs VERA, IRON, QURE: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Ultragenyx Pharmaceutical's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ultragenyx Pharmaceutical Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ultragenyx Pharmaceutical's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Ultragenyx Pharmaceutical's Tariff Resilience Score falls into.


MEX:RARE
70GF Score
Ultragenyx Pharmaceutical Inc MEX:RARE
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 6 mean?
Ultragenyx Pharmaceutical (MEX:RARE) has a Tariff Resilience Score of 6 as of Jul. 15, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Ultragenyx Pharmaceutical ranks #329 out of 1370 companies in the Biotechnology industry, placing it in the top 24%.
Is Ultragenyx Pharmaceutical's Tariff Resilience Score too high?
Ultragenyx Pharmaceutical's current Tariff Resilience Score is 6. The Biotechnology industry median Tariff Resilience Score is 4.00. Ultragenyx Pharmaceutical's value of 6 is 50% above this industry median. Based on the distribution chart, Ultragenyx Pharmaceutical ranks #329 out of 1370 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Ultragenyx Pharmaceutical has a GF Score™ of 70/100, reflecting its overall financial health beyond just this single metric.
How does Ultragenyx Pharmaceutical's Tariff Resilience Score compare to VERA and IRON?
According to the Biotechnology industry distribution chart, Ultragenyx Pharmaceutical ranks #329 out of 1370 companies for Tariff Resilience Score. This places Ultragenyx Pharmaceutical in the top 24% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Ultragenyx Pharmaceutical's value of 6 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,370 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ultragenyx Pharmaceutical's current Tariff Resilience Score of 6 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ultragenyx Pharmaceutical's current Tariff Resilience Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ultragenyx Pharmaceutical stock overvalued right now?
Ultragenyx Pharmaceutical (MEX:RARE) has a current Tariff Resilience Score of 6. The stock's GF Value™ is MXN1,699.44, compared to a current price of MXN1,150.56 — trading 32.3% below its estimated fair value. The current Tariff Resilience Score is 6 and 50% above the Biotechnology industry median of 4.00. Ultragenyx Pharmaceutical's overall GF Score™ is 70/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Ultragenyx Pharmaceutical (MEX:RARE), the current Tariff Resilience Score is 6 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ultragenyx Pharmaceutical (MEX:RARE) Overvalued in 2026?

Based on GuruFocus' analysis, Ultragenyx Pharmaceutical stock appears to be undervalued. The current stock price of MXN1,150.56 is trading 32.3% below its estimated GF Value™ of MXN1,699.44.

Key valuation signals for MEX:RARE:

  • Tariff Resilience Score: 6
  • GF Value™: MXN1,699.44 vs. price of MXN1,150.56 (32.3% below fair value)
  • GF Score™: 70/100 with 5 warning signs
  • Industry Position: 50% above the Biotechnology median (#329 of 1370)

No single metric tells the full story. See the MEX:RARE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ultragenyx Pharmaceutical Business Description

Address 60 Leveroni Court, Novato, CA, USA, 94949
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.
70GF Score

Get the complete analysis for MEX:RARE

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,150.56
Price
MXN1,699.44
GF Value